Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

53.64USD
9:00pm BST
Change (% chg)

$-0.01 (-0.02%)
Prev Close
$53.65
Open
$53.40
Day's High
$53.73
Day's Low
$53.05
Volume
1,614,971
Avg. Vol
2,136,520
52-wk High
$70.04
52-wk Low
$49.97

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb Announces Dividend
Thursday, 14 Jun 2018 

June 14 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ANNOUNCES DIVIDEND.BRISTOL-MYERS SQUIBB CO - DECLARED A QUARTERLY DIVIDEND OF FORTY CENTS PER SHARE ON $.10 PAR VALUE COMMON STOCK OF CORPORATION.  Full Article

Bristol-Myers Says Patients In Opdivo Plus Low-Dose Yervoy Trial Reported Fewer Kidney Cancer Symptoms
Friday, 1 Jun 2018 

June 1 (Reuters) - Bristol-Myers Squibb Co ::OPDIVO (NIVOLUMAB) PLUS LOW-DOSE (1MG/KG) YERVOY (IPILIMUMAB) PROVIDED SIGNIFICANT AND SUSTAINED HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN CHECKMATE -214 STUDY.BRISTOL-MYERS SQUIBB - PATIENTS IN OPDIVO PLUS LOW-DOSE YERVOY ARM REPORTED FEWER KIDNEY CANCER SYMPTOMS AS MEASURED BY NCCN FKSI-19.BRISTOL-MYERS SQUIBB - IN PHASE 3 CHECKMATE -214 TRIAL, TREATMENT WITH OPDIVO PLUS LOW-DOSE YERVOY LED TO STATISTICALLY SIGNIFICANT DIFFERENCES.BRISTOL-MYERS SQUIBB - PATIENTS IN STUDY TREATED WITH OPDIVO PLUS LOW-DOSE YERVOY REPORTED SIGNIFICANT BENEFITS IN DISEASE-RELATED SYMPTOMS.  Full Article

Idera Pharmaceuticals Enters Into A Clinical Trial Collaboration And Supply Agreement With Bristol-Myers Squibb
Thursday, 24 May 2018 

May 24 (Reuters) - Bristol-Myers Squibb Co ::IDERA PHARMACEUTICALS SAYS EFFECTIVE MAY 18, 2018 ENTERED INTO A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH BRISTOL-MYERS SQUIBB.IDERA PHARMACEUTICALS - DEAL TO CLINICALLY EVALUATE COMBINATION OF CO'S TLR-9 AGONIST IMO-2125 WITH BMS'S THERAPY YERVOY.IDERA PHARMACEUTICALS INC - BMS GRANTED CO NON-EXCLUSIVE, NON-TRANSFERRABLE, ROYALTY-FREE LICENSE UNDER INTELLECTUAL PROPERTY TO USE YERVOY IN TRIAL.IDERA PHARMACEUTICALS - WILL SPONSOR, FUND, CONDUCT CO'S OPEN-LABEL, MULTI-CENTER PHASE 3 CLINICAL TRIAL OF TILSOTOLIMOD IN COMBINATION WITH YERVOY.IDERA PHARMACEUTICALS INC - UPON TERMINATION OF DEAL, LICENSES GRANTED TO CO TO USE YERVOY(REG) IN TRIAL WILL TERMINATE.  Full Article

Advantagene Announces Clinical Trial Collaboration
Friday, 27 Apr 2018 

April 27 (Reuters) - Bristol-Myers Squibb Co ::ADVANTAGENE ANNOUNCES CLINICAL TRIAL COLLABORATION.ADVANTAGENE INC SAYS COMPANY ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH BRISTOL-MYERS SQUIBB.ADVANTAGENE - COLLABORATION TO EVALUATE SAFETY, EFFICACY OF CO'S INVESTIGATIONAL GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY COMBINED WITH BRISTOL'S OPDIVO.ADVANTAGENE - ITS INVESTIGATIONAL GMCI COMBINED WITH OPDIVO IS TO TREAT NEWLY DIAGNOSED MALIGNANT GLIOMA PATIENTS GETTING SURGERY WITH/WITHOUT TEMOZOLOMIDE.  Full Article

CEO Says Bristol-Myers Still A Growth Company
Thursday, 26 Apr 2018 

April 26 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB SEES CONTINUED GROWTH IN ANTICOAGULANT MARKET SHARE FOR ELIQUIS.BRISTOL-MYERS CEO SAYS CONTINUES TO SEE BMS AS A GROWTH COMPANY AND OPDIVO AS A GROWTH FRANCHISE.  Full Article

Bristol-Myers Squibb Reports Q1 GAAP Earnings Per Share $0.91
Thursday, 26 Apr 2018 

April 26 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB REPORTS FIRST QUARTER FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $0.94.Q1 GAAP EARNINGS PER SHARE $0.91.Q1 REVENUE $5.2 BILLION VERSUS I/B/E/S VIEW $5.23 BILLION.Q1 EARNINGS PER SHARE VIEW $0.85 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 GAAP EARNINGS PER SHARE $2.70 TO $2.80.QTRLY SPRYCEL WORLDWIDE REVENUE $438 MILLION VERSUS $463 MILLION REPORTED LAST YEAR.QTRLY OPDIVO WORLDWIDE REVENUE $1,511 MILLION VERSUS $1,127 MILLION REPORTED LAST YEAR.INCREASING 2018 NON-GAAP EPS GUIDANCE RANGE FROM $3.15 - $3.30 TO $3.35 - $3.45.QTRLY ELIQUIS WORLDWIDE REVENUE $1,506 MILLION VERSUS $1,101 MILLION REPORTED LAST YEAR.QTRLY YERVOY WORLDWIDE REVENUE $249 MILLION VERSUS $330 MILLION REPORTED LAST YEAR.SEES 2018 WORLDWIDE REVENUES INCREASING IN MID-SINGLE DIGITS.U.S. REVENUES INCREASED 1% TO $2.8 BILLION IN THE QUARTER COMPARED TO THE SAME PERIOD A YEAR AGO.QTRLY INTERNATIONAL REVENUES INCREASED 10%.  Full Article

Bristol-Myers Says FDA Approves Opdivo + Yervoy Combo For Treating Patients With Renal Cell Carcinoma
Monday, 16 Apr 2018 

April 16 (Reuters) - Bristol-Myers Squibb Co ::U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) + YERVOY® (IPILIMUMAB) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH INTERMEDIATE- AND POOR-RISK ADVANCED RENAL CELL CARCINOMA.BRISTOL-MYERS SQUIBB - IN PHASE 3 CHECKMATE -214 CLINICAL TRIAL, OPDIVO + YERVOY COMBINATION DEMONSTRATED A SIGNIFICANT INCREASE IN OVERALL SURVIVAL.BRISTOL-MYERS SQUIBB - IN PHASE 3 CHECKMATE -214 TRIAL, OPDIVO + YERVOY ALSO DELIVERED DURABLE RESPONSES, WITH HIGHER OBJECTIVE RESPONSE RATE VERSUS SUNITINIB.  Full Article

Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies
Friday, 13 Apr 2018 

April 13 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB AND ILLUMINA ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE COMPANION DIAGNOSTICS FOR BRISTOL-MYERS SQUIBB’S ONCOLOGY IMMUNOTHERAPIES.EXPANDS ILLUMINA'S ONCOLOGY OFFERINGS FOR NEXTSEQ 550DX.COS PLAN TO DEVELOP A DIAGNOSTIC VERSION OF ILLUMINA TRUSIGHT ONCOLOGY 500 ASSAY TO MEASURE POTENTIALLY PREDICTIVE GENOMIC BIOMARKERS.  Full Article

U.S. FDA Accepts Bristol-Myers Squibb's Application For Opdivo Plus Yervoy
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Bristol-Myers Squibb Co ::U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) FOR PREVIOUSLY TREATED PATIENTS WITH MSI-H OR DMMR METASTATIC COLORECTAL CANCER FOR PRIORITY REVIEW.U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) FOR PREVIOUSLY TREATED PATIENTS WITH MSI-H OR DMMR METASTATIC COLORECTAL CANCER FOR PRIORITY REVIEW.BRISTOL-MYERS SQUIBB CO - ‍FDA ALSO GRANTED OPDIVO PLUS YERVOY COMBINATION BREAKTHROUGH THERAPY DESIGNATION FOR THIS POTENTIAL INDICATION​.BRISTOL-MYERS SQUIBB CO - FDA ACTION DATE FOR FURTHER REGULATION ON THE SBLA IS JULY 10, 2018.  Full Article

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma
Monday, 26 Mar 2018 

March 26 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF OPDIVO FOUR-WEEK DOSING SCHEDULE FOR ADVANCED MELANOMA AND PREVIOUSLY TREATED RENAL CELL CARCINOMA.BRISTOL-MYERS SQUIBB CO - ‍CHMP RECOMMENDATION OF OPDIVO WILL NOW BE REVIEWED BY EUROPEAN COMMISSION​.BRISTOL-MYERS - CHMP ALSO RECOMMENDED APPROVAL OF TWO-WEEK OPDIVO DOSING OPTION OF 240 MG TO REPLACE WEIGHT-BASED DOSING FOR APPROVED MONOTHERAPIES IN EU.BRISTOL-MYERS SQUIBB CO - CHMP RECOMMENDATION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION.  Full Article

RPT-BUZZ-U.S. stocks weekly: Triple crown

** At first, NYSE Composite was ticked off , and S&P Futures stepped into sticky patch